Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.APP Pharma announces key management changes
The company has also announced that Richard Tajak has been appointed executive vice president and CFO, succeeding Lisa Gopala. Both Patrick and Lisa served in their roles under
The company has also announced that Richard Tajak has been appointed executive vice president and CFO, succeeding Lisa Gopala. Both Patrick and Lisa served in their roles under
Merck extended the deadlines to allow claimants and their counsel additional time to complete the enrollment process and for the claims administrator and the company to continue to
The study evaluated the safety and immunogenicity of Recothrom for patients undergoing skin grafting for burns. Topical application of Recothrom using a pump spray device was well tolerated
The proceeds will primarily be used to fund R&D aimed at the identification and validation of protein biomarkers with the goal of finding high potential diagnostic candidates. Christopher
After the equity issuance, Bio-Bridge shall control 51% of the outstanding capital stock of the Xinheng Baide Biotechnology (the seller) for a total cash purchase price of RMB6
Following FDA review of this investigational new drug application (IND), the company plans to initiate a Phase I clinical trial of PX-866. Robert Kirkman, president and CEO of
Under the terms of the agreement, all outstanding shares of Cornerstone’s common stock will be converted into and exchanged for shares of Critical Therapeutics’s common stock and all
The Quill Self-Retaining System (SRS) Polydioxanone (PDO) is a longer-lasting absorbable suture, which is typically used for deeper tissue closures. These smaller diameter sizes incorporate a new design
Ms Shi has 10 years’ working experience in the fields of financial control, auditing and business analysis in both China and the US. Since 2005, she has acted
Athena-1 is the first of several Phase IV Letairis (ambrisentan 5mg and 10mg tablets) studies Gilead plans to initiate in 2008 and 2009. Letairis is currently approved as